Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Poor formulation information in published pediatric drug trials.

Joseph F Standing1, Zahra F Khaki, Ian C K Wong

  • 1School of Pharmacy, University of London, London, United Kingdom.

Pediatrics
|October 4, 2005
PubMed
Summary

Pediatric drug trials often lack adequate formulation information, hindering reproducibility and clinical use. Authors must report full formulation details to ensure the validity and reliability of pediatric medication studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Childhood Maltreatment and Adult Multimorbidity.

JAMA network open·2026
Same author

Psychiatric and neurological predictors of early ADHD medication discontinuation across the lifespan: a multinational study.

BMJ mental health·2026
Same author

A Target Trial Emulation to Investigate Kidney Protection from Statin Initiation in Adults with Normal Kidney Function.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Abrupt discontinuation and tapering of antipsychotics in older adults with dementia: a target trial emulation study.

The lancet. Healthy longevity·2026
Same author

Potential interactions between SSRIs and DOACs: population-based cohort and case-crossover study.

BJGP open·2026
Same author

Association between gabapentinoid treatment, concurrent use with opioid or benzodiazepine and the risk of drug poisoning: A self-controlled case series study.

PLoS medicine·2026

Area of Science:

  • Pediatric Pharmacology
  • Clinical Trial Methodology
  • Pharmaceutical Sciences

Background:

  • International Conference on Harmonisation guidelines recommend appropriate formulations for pediatric drug trials.
  • Economic constraints and limited formulation research often lead to the use of non-ideal formulations in pediatric studies.
  • Accurate reporting of formulation and administration methods is crucial for the reliability and validity of pediatric drug trial results.

Purpose of the Study:

  • To evaluate the adequacy of pediatric drug formulation information reported in recently published clinical trials involving children under 12 years of age.
  • To assess whether published pediatric oral medication studies provide sufficient detail for accurate reproduction and clinical implementation.

Main Methods:

  • A hand-search of 3992 papers published between July 2002 and June 2004 in 10 highly cited journals (5 pediatric, 5 general medicine) was conducted.

Related Experiment Videos

  • Two independent reviewers extracted data on drug formulation and administration for oral medication studies including children younger than 12 years.
  • Papers were classified based on the adequacy of reported formulation information: adequate, some, or none.

    • Main Results:

    • Of 76 eligible studies, only 28 (37%) provided adequate formulation information for accurate reproduction.
    • Twenty-six percent (20/76) of studies failed to report the formulation used.
    • Among studies reporting formulation, only 49% (37/76) utilized a pediatric-specific formulation (e.g., liquid, chewable tablet).
    • No significant differences in reporting adequacy were observed between pediatric and general medical journals.

    Conclusions:

    • Highly cited journals frequently publish pediatric drug trial reports with inadequate formulation details, compromising study validity and reliability.
    • Authors are urged to consistently provide comprehensive formulation information in all pediatric clinical trial publications.
    • Improved reporting standards are necessary to enhance the clinical applicability and reproducibility of pediatric medication research.